Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives.
SARS-CoV-2
monoclonal antibodies
prophylaxis
therapy
variants
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
06 Dec 2021
06 Dec 2021
Historique:
received:
18
11
2021
revised:
29
11
2021
accepted:
30
11
2021
entrez:
28
12
2021
pubmed:
29
12
2021
medline:
29
12
2021
Statut:
epublish
Résumé
Monoclonal antibodies (mAbs) have been known since the 1970s. However, their therapeutic potential in the medical field has recently emerged, with the advancement of manufacturing techniques. Initially exploited mainly in the oncology field, mAbs have become increasingly relevant in Infectious Diseases. Numerous mAbs have been developed against SARS-CoV 2 and have proven their effectiveness, especially in the management of the mild-to-moderate disease. In this review, we describe the monoclonal antibodies currently authorized for the treatment of the coronavirus disease 19 (COVID-19) and offer an insight into the clinical trials that led to their approval. We discuss the mechanisms of action and methods of administration as well as the prophylactic and therapeutic labelled indications (both in outpatient and hospital settings). Furthermore, we address the critical issues regarding mAbs, focusing on their effectiveness against the variants of concern (VoC) and their role now that a large part of the population has been vaccinated. The purpose is to offer the clinician an up-to-date overview of a therapeutic tool that could prove decisive in treating patients at high risk of progression to severe disease.
Identifiants
pubmed: 34959672
pii: ph14121272
doi: 10.3390/ph14121272
pmc: PMC8707981
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Microb Cell Fact. 2021 Apr 22;20(1):88
pubmed: 33888152
Science. 2020 Sep 18;369(6510):1505-1509
pubmed: 32703908
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Biol Chem. 2019 Feb 25;400(3):383-393
pubmed: 30465712
Methods Mol Biol. 2019;1904:109-145
pubmed: 30539468
Appl Microbiol Biotechnol. 2021 Aug;105(16-17):6315-6332
pubmed: 34423407
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Lancet. 2022 Feb 12;399(10325):665-676
pubmed: 35151397
Rev Med Virol. 2021 Nov;31(6):e2231
pubmed: 33724631
MAbs. 2021 Jan-Dec;13(1):1860476
pubmed: 33459118
Clin Microbiol Infect. 2022 Jan;28(1):139.e5-139.e8
pubmed: 34537363
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
MAbs. 2020 Jan-Dec;12(1):1854149
pubmed: 33319649
Cell. 2021 Jun 10;184(12):3086-3108
pubmed: 34087172
Int J Pharm. 2021 Jun 15;603:120686
pubmed: 33964339
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Drug Discov Today. 2021 Nov;26(11):2619-2636
pubmed: 34332100
Cell. 2021 Apr 1;184(7):1804-1820.e16
pubmed: 33691139
Clin Dev Immunol. 2013;2013:297120
pubmed: 24106516
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Clin Microbiol Infect. 2019 Jan;25(1):60-64
pubmed: 29715552
J Infect Dis. 2012 Feb 15;205(4):635-8
pubmed: 22184728
Monoclon Antib Immunodiagn Immunother. 2021 Apr;40(2):36-49
pubmed: 33900819
Viruses. 2021 Oct 19;13(10):
pubmed: 34696536
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
JAMA. 2020 Jul 14;324(2):131-132
pubmed: 32539093
Nat Commun. 2021 Jan 12;12(1):288
pubmed: 33436577
Cell Rep Med. 2021 Mar 16;2(3):100218
pubmed: 33649747
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Viruses. 2021 Apr 07;13(4):
pubmed: 33916927
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
N Engl J Med. 2018 Apr 19;378(16):1469-1472
pubmed: 29513615
Cochrane Database Syst Rev. 2021 Sep 2;9:CD013825
pubmed: 34473343
Pediatrics. 1998 Sep;102(3):531-7
pubmed: 9724660
Cell Host Microbe. 2021 May 12;29(5):747-751.e4
pubmed: 33887205
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Nature. 2020 Mar;579(7800):482-483
pubmed: 32203366
Science. 2021 Mar 26;371(6536):1379-1382
pubmed: 33597220
Biomed J. 2021 Mar;44(1):7-17
pubmed: 33589377
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Science. 2020 May 29;368(6494):948-950
pubmed: 32393526
Int J Mol Sci. 2021 Mar 17;22(6):
pubmed: 33802650
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Nat Commun. 2020 Aug 27;11(1):4303
pubmed: 32855401
Nat Rev Immunol. 2020 Oct;20(10):633-643
pubmed: 32782358
N Engl J Med. 2021 Oct 7;385(15):1382-1392
pubmed: 34260849
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Iran J Med Sci. 2021 May;46(3):151-168
pubmed: 34083848
Nat Rev Immunol. 2018 Jan;18(1):46-61
pubmed: 29063907
Clin Immunol. 2021 Jan;222:108634
pubmed: 33217545
Vaccine. 2021 Apr 15;39(16):2280-2287
pubmed: 33731271
J Virol. 2020 Feb 14;94(5):
pubmed: 31826992
JAMA. 2021 Jul 6;326(1):46-55
pubmed: 34081073